Clinical trials: Severe Burn

Hypercatabolic Status Related to Severe Burn

Study of Tolerability and Efficacy of BVS857 in Severe Burn Subjects

• Terminated
• Age: 18 to 60 years
• Phase 2
• Injection or infusion
• Results posted

Study of tolerability and efficacy of BVS857 in severe burn subjects over 8 weeks and 15 weeks

Trial name

NCT02074995

Testing

BVS857

Where

United States

Volunteers

1 people

Sponsor

Novartis Pharmaceuticals